Erythropoietin (EPO) ELISA Kit

Immunoassay for detection and measurement of human erythropoietin

Erythropoietin (EPO) ELISA Kit

Immunoassay for detection and measurement of human erythropoietin

Erythropoietin (EPO) ELISA Kit
1 Kit
970 USD
Catalog # 01630

Immunoassay for detection and measurement of human erythropoietin

What's Included

  • 96-well Microtiter Plate Precoated with Capture Antibody
    •  (12 strips of 8 wells)
  • Assay Buffer
  • Sample Diluent
  • EPO Standards
    •  0 - 100 mU/mL, calibrated against the International Standard for Recombinant-DNA-Derived EPO (NIBSC code 87/684)
  • Labeled Detection Antibody
  • Horseradish Peroxidase Conjugate
  • Tetramethylbenzidine (TMB) Substrate Solution
  • Stop Solution
  • 10X Wash Buffer
  • Adhesive Covers
  • Instruction Manual

Overview

The glycoprotein EPO is the main physiological regulator of red blood cell formation. The EPO ELISA Kit is a rapid 3-step enzyme-linked immunosorbent assay (ELISA) designed for the quantitative measurement of natural and recombinant human EPO. The assay uses two monoclonal antibodies raised against human urinary EPO. These antibodies bind two non-overlapping epitopes on the EPO polypeptide and show high-affinity binding to both natural and recombinant EPO. The range of detection for the kit is 1.6 - 100 mU/mL. The EPO ELISA Kit has an assay time of approximately 3 hours.
Subtype
Complete Kits
Cell Type
Other
Species
Human
Application
ELISA
Area of Interest
Drug Discovery and Toxicity Testing
CAS Number
108-32-7, 872-50-4, 111-46-6, 7664-93-9

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
01630
Lot #
16E68690 or higher
Language
English
Document Type
Technical Manual
Catalog #
01630
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
01630
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
01630
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
01630
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
01630
Lot #
All
Language
English
Document Type
Safety Data Sheet 5
Catalog #
01630
Lot #
All
Language
English
Document Type
Safety Data Sheet 6
Catalog #
01630
Lot #
All
Language
English
Document Type
Safety Data Sheet 7
Catalog #
01630
Lot #
All
Language
English
Document Type
Safety Data Sheet 8
Catalog #
01630
Lot #
All
Language
English
Document Type
Safety Data Sheet 9
Catalog #
01630
Lot #
All
Language
English
Catalog #
01630
Lot #
All
Language
English
Catalog #
01630
Lot #
All
Language
English
Catalog #
01630
Lot #
All
Language
English
Catalog #
01630
Lot #
All
Language
English
Catalog #
01630
Lot #
All
Language
English
Catalog #
01630
Lot #
All
Language
English
Catalog #
01630
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (4)

The blood in systemic disorders. Spivak JL Lancet 2000 MAY

Abstract

* The high rate of proliferation required of the bone marrow renders it highly susceptible to the influence of external factors. * Anaemia is the most common haematological abnormality seen in systemic disorders. * In the anaemia of chronic disease, erythropoietin production is reduced and proliferation of erythroid progenitor cells is also impaired; this anaemia can generally be alleviated by correction of the underlying disease process. * The status of the endocrine system must always be considered in evaluation of a normocytic, normochromic anaemia. * Anaemia in infection can be due to host or parasite factors or to the treatment administered. * Anaemia due to malignant disease responds to erythropoietin therapy in many cases; failure to respond is a poor prognostic sign.
A specific in vitro bioassay for measuring erythropoietin levels in human serum and plasma. Wognum AW et al. Blood 1990 OCT

Abstract

The accurate measurement of biologically active erythropoietin (Ep) in human serum and plasma using present in vivo and in vitro bioassays is difficult because of the presence of both inhibitors and non-Ep stimulators of erythropoiesis. We have developed a simple procedure to quantitatively purify Ep from serum and plasma for subsequent testing in the phenylhydrazine-treated mouse spleen cell assay. The method involves absorption of Ep to an immobilized high-affinity anti-Ep monoclonal antibody and acid elution of the antibody-bound material. After neutralization, the eluted EP is then tested directly in the in vitro bioassay without interference by other serum proteins. By using magnetic beads as a solid support for the antibody, washing and elution steps can be performed rapidly and efficiently. Recoveries of Ep after this procedure show very little sample-to-sample variation and are consistently between 45% and 55%, which is close to the maximum binding expected for the anti-Ep antibody. Coupled with the 7.4-fold concentration that this procedure affords, there is an overall increase in sensitivity of three- to fourfold, which makes this assay suitable for accurately measuring Ep levels in patients with below-average titers. Results with this magnetic bead assay indicate that accurate and reproducible estimates for Ep levels in the serum and plasma from healthy donors as well as from patients with hematologic disorders can be obtained. Titers of biologically active Ep in the sera from a group of patients with either leukemia or lymphoma were found to be elevated, and the values correlated well with titers of immunoreactive Ep measured in the Ep radioimmunoassay. Because of its specificity and high sensitivity, the magnetic bead assay is a valuable alternative to immunoassays for the measurement of elevated, normal, and even subnormal Ep levels in human serum and plasma.
Immunochemical analysis of monoclonal antibodies to human erythropoietin. Wognum AW et al. Experimental hematology 1990 MAR

Abstract

We recently reported the development of three monoclonal antibodies (MoAbs) to biologically active human erythropoietin (Ep). In the present study, we investigated the epitope specificity of these three antibodies, as well as their reactivity with Eps derived from species other than man. All three antibodies reacted with the Ep polypeptide itself, rather than with its carbohydrate moieties. Moreover, all three antibodies recognized separate nonoverlapping epitopes. Further studies with reduced/alkylated Ep and with sodium dodecyl sulfate-denatured Ep suggested that two of the MoAbs, anti-Ep-2 and anti-Ep-16, were specific for conformational, nonlinear determinants on the Ep molecule, whereas the third MoAb, anti-Ep-26, appeared to recognize a linear epitope. However, anti-Ep-26 did not react with synthetic peptides representing the 26 amino-, the 99-129 mid-region, or the 10 carboxy-terminal residues of Ep, nor with trypsin-, chymotrypsin-, or V8 protease-digested fragments of Ep. When tested with Ep from different species, the neutralizing capabilities of the three MoAbs were clearly different. Comparing their effectiveness against baboon, ovine and murine Ep, antibody 2 was most effective at neutralizing baboon Ep, antibody 16 was most effective against murine Ep, and antibody 26 showed little reactivity with any of these nonhuman Eps. Because these various Eps readily stimulate across species barriers, it is likely that the receptor binding domain on Ep has remained relatively conserved during evolution. Our results therefore suggest that the neutralizing capacity of our three anti-Ep MoAbs is caused not by binding directly to the Ep receptor binding domain on Ep, but by binding to distant regions, causing conformational changes in Ep, or by binding to regions close to the binding site, steric hindrance.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.